http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 한광협(Kwang Hyub Han) (검색결과 147 건)
- 무료
- 기관 내 무료
- 유료
-
-
한광협 ( Kwang Hyub Han ),김승업 ( Seung Up Kim ) 대한내과학회 2008 대한내과학회지 Vol.74 No.5
Progressive liver fibrosis is a similar feature of all chronic liver diseases and eventually develops liver cirrhosis. The prognosis and treatment plans of chronic liver diseases depend strongly on the degree of liver fibrosis. These facts raise clinical interests in quantifying liver fibrosis. Although liver biopsy has been the gold standard for assessment of liver fibrosis, it has some technical limitations and risks. Accordingly, an increasing need for alternative non-invasive method to quantify liver fibrosis has been a major challenge that has stimulated search for new non-invasive methods. Such methods for diagnosing liver fibrosis have progressed significantly over the last few years notably with the appearance of several serological markers which have been reported to predict the presence of significant fibrosis or cirrhosis in patients with chronic liver disease with considerable accuracy. However, complicated calculation, cost problems, and influences of extrahepatic conditions make it less accessible to clinicians. Recently, liver stiffness measurement using FibroScan(R) is emerging as a new diagnostic method for liver fibrosis. It is totally non-invasive and reproducible and gives an immediate result without intra- and inter-observer variability. Its clinical use in comparison with liver biopsy and several available serologic markers is now intensively being investigated. Here, we review the currently available data on FibroScan(R).(Korean J Med 74:463-471, 2008)
-
-
-
-
한광협 ( Kwang Hyub Han ),김승업 ( Seung Up Kim ) 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.2(S)
Liver fibrosis is the results of chronic injury and a similar feature of all chronic liver diseases. Beyond being a marker of injury, it appears to play a direct role in the pathogenesis of hepatocellular dysfunction and portal hypertension. Furthermore, the prognosis and treatment plans of chronic liver diseases strongly depend on the degree of liver fibrosis. Thus, from a clinical management viewpoint, accurately assessing the extent and progression of fibrosis is important and clinical interests are being raised in quantifying liver fibrosis. Although liver biopsy has been the gold standard for assessment of liver fibrosis, it has some technical limitations and risks. Accordingly, an increasing need for alternative noninvasive method to quantify liver fibrosis has been a major challenge that has stimulated search for new noninvasive methods. Such methods for diagnosing liver fibrosis have progressed significantly over the last few decades notably with the appearance of several serological markers, which have been reported to predict the presence of significant fibrosis or cirrhosis in patients with chronic liver disease with considerable accuracy. However, complicated calculation and influences of extrahepatic conditions make it less accessible to clinicians. Recently, transient elastography using FibroScan(R) is emerging as a new diagnostic method for liver fibrosis. It is totally noninvasive and reproducible and gives an immediate result with low intra- and inter-observer variability. Here, we review the currently available data on transient elastography for assessing liver fibrosis.
-
원발성 간암환자의 간염 바이러스 감염유형에 따른 임상양상 및 예후
한광협(Kwang Hyub Han),문희용(Hee Yong Moon),김범수(Bum Soo Kim),백용한(Yong Han Paik),전재윤(Chae Yoon Chon),문영명(Young Myoung Moon),강진경(Jin Kyung Kang),박인서(In Suh Park) 대한내과학회 2001 대한내과학회지 Vol.60 No.1
Background : Hepatocellular carcinoma(HCC) is one of the important causes of cancer-related mortality and morbidity in East Asia, including Korea. Most of the hepatocellular carcinoma in Korea are associated with hepatitis B and C virus infection. The clinical characteristics and prognosis of the patients with HCC were evaluated in relation to the type of hepatitis virus. Methods : A retrospective analysis of the clinical data and survival rate was done in 603 patients(M:F=4.9:1, mean age; 54.2 years) who were admitted to Yonsei medical center from April, 1991 through April, 1994. Results : Among 603 patients, tests for HBsAg and anti-HCV was done simultaneously in 455 patients. Out of the 455 HCC patients, 303 patients (66.6%) were classified as Group B(HBsAg+ve, anti-HCV-ve), 102 patients (22.4%) were classified as Group C (HBsAg-ve, anti-HCV+ve), 45 patients (9.9%) were classified as Group non-BC (HBsAg-ve, anti-HCV-ve), and 5 patients (1.1%) were classified as Group BC (HBsAg+ve, anti-HCV+ve). The mean age of the patients in Group C was older than that of Group B (64.9 vs. 51.3 yr) (p<0.05). Liver cirrhosis was frequently noticed in Group C than Group B (84.3 vs. 68.0%) (p<0.05). The number of the patients whose serum FP level was elevated (>400 ng/mL) was significantly higher in Group B than in Group C (70.0 vs. 52.0%)(p<0.05). According to the gross type, nodular type was more common in Group C than in Group B(72.0 vs. 38.1%) (p<0.01). The incidence of portal vein thrombosis was significantly lower in Group C compared with that in Group B (16.7 vs. 31.4%)(p<0.05). The number of the patients whose tumor size of less than 5 cm was significantly higher in Group C than in Group B (35.3 vs. 17.8%) (p<0.05). Using multivariant analysis, independent prognostic factors were found to be Child grading, FP level, size of the tumor, gross type, and the type of hepatitis virus. The cumulative survival rate of 1, 2, and 3 year in each Group was 31.5%, 17.5%, and 10.8%, respectively in Group B, and 55.7%, 30.2%, and 21.6%, respectively in Group C. The median duration of survival of Group B was significantly shorter than that of Group C(5.0 vs. 13 months)(p<0.05). Conclusion : About 90 % of HCC was associated with hepatitis B or C viral infection in Korea. Hepatitis B virus associated HCC had poorer prognosis compared with hepatitis C virus associated HCC in Korea.(Korean J Med 60:22-31, 2001)
-
원발성 간암과 감별이 어려웠던 비전형적인 간혈관종 1예
한광협(Kwang Hyub Han),백용한(Yong Han Paik),전재윤(Chae Yoon Chon),문영명(Young Myoung Moon),김진석(Jin Suk Kim),고준상(Jun Sang Ko),정재연(Jae Youn Cheong),조영준(Young Jun Cho),최병현(Byung Hyun Choi) 대한소화기학회 2000 대한소화기학회지 Vol.35 No.2
Hepatocellular carcinoma is one of the major cancers in Korea. Early detection and diagnosis are the most important for the treatment of hepatocellular carcinoma. Ultrasonography combined with the measurement of serum α-fetoprotein is an effective screening method to detect small hepatocellular carcinoma. A 53-year-old man who had chronic hepatitis B was referred to our hospital under the suspicion of having hepatocellular carcinoma. Ultrasonogrphy had revealed a 3 cm diameter hyperechoic mass, suggesting hemangioma. Magnetic resonance (MR) imaging was performed for suspicion of having hepatocellular carcinoma due to elevated serum α-fetoprotein level. Since MR imaging was consistent with possible hepatocellular carcinoma, but not specific for hemangioma, red blood cell scan, needle aspiration biopsy, and angiography were performed. However, those results were not conclusive. Thus, the patient was followed at regular intervals. Since serum α-fetoprotein level became normal, but tumor size was not changed during long term follow-up, we diagnosed the lesion as atypical hemangioma. (Kor J Gastroenterol 2000;35:253 - 257)
-
만성 B형 활동성 간염에서 poly ( A ). poly ( U ) 의 치료 효과
함기백,김원호,한광협,임대순,전재윤,문영명,강진경,박인서,최흥재,윤정구 ( Ki Baik Hahm,Won Ho Kim,Kwang Hyub Han,Dae Soon Yim,Chae Yoon Chon,Young Myung Moon,Jin Kyung Kang,In Suh Park,Heung Jai Choi,Jung Koo Youn ) 대한소화기학회 1992 대한소화기학회지 Vol.24 No.3
The two major approaches to the treatment of chronic hepatitis B are 1) directed toward the eradication of the virus and 2) designed to modulate cellular and humoral immunity. Progress has been made in the development of antiviral chemotherapeutic agents for hepatitis B, but as yet no safe and reliably effective treatment or combmations of treatments are available. It has been demonstrated that interferon is useful in suppressing hepatitis B viral replication, but the relatively low response rate of Asian patients to interferon treatment has been documented due to the fact that mostly they acguired infections perinatally or during childhood. Poly(A). poly(U) is a double stranded helical ribopolyuncleotide complex, which stimulates both humoral and cell mediated immune response, and enhances the splenic NK activity as well as induces the production of the interferon. In this study, we have measured sequentially the leveils of alanine aminotransferase (ALT) and 2, 5-oligoadenylate synthetase (2-5 AS) activities and hepatitis B viral markers in patients with histologically proven chronic active heaptitis after weekly intravenous injection of poly(A). poly(U) to find out that poly(A). poly(U) may be used as the therapeutic agent in the treatment of chronic active hepatitis B. The results were as follows: ALT levels after the weekly administrations of poly(A).poly(U) have declined significantly to the normal level except one case as times passed, especially after 5 weeks. Serum 2-5 AS activities were elevated significantly after the administration of poly(A).poly(U). The complete responses were noted in four cases out of eleven cases (36.4%) until 5 months after discontinuance of poly(A).poly(U). The partial responses were noted in five cases (45.5%). No specific side effects were noted except the light-headness just one time in only one case. In conclusion, the administration of poly(A).poly(U) in the patients with chronic active hepatitis B seems to be effective, simple and safe method, although more extensive and detailed immunologic researches are required.
-
각종 간질환 환자에서 혈중 lipoprotein ( a ) 농도의 변화
함기백,김원호,한광협,전재윤,강진경,박인서,최홍재 ( Ki Baik Hahm,Won Ho Kim,Kwang Hyub Han,Chae Yoon Chon,Jin Kyung Kang,In Suh Park,Heung Jai Choi ) 대한소화기학회 1992 대한소화기학회지 Vol.24 No.2
Lipoprotein (a) [Lp (a)] is a LDL-like lipoprotein whose concentrations in plasma are significantly are correlated with atherosclerosis. The characteristic protein compoment of Lp (a) is apoliporotein (a) which is linked to apolipoprotein B-100 by disulfide bonds. Although Lp (a) might play an important role in the development of premature atherosclerotic vascular lesions, only scarse information about the metabolism of this lipoprotein is available. The major site of synthesis of Lp (a) appers to be the liver because it was found that a complete conversion of the Lp (a) phenotype of thc receipient to that of the donor occurs after liver transplantation and presence of apo (a) mRNA in human liver and hepatoma cell line. Until the present time, little information is available about determining the influence of liver disease on Lp (a) concentration. This study was designed to find out the changes of Lp (a) concentrations in 88 patients with various liver diseases, diagnosed histologically through the peritoneoscopic liver biopsy. The Lp (a) concentrations were checked by the method of radioimmunoassay. The mean Lp (a) concentrations of CAH with LC (6.1+4.8 mg/ml) and LC group (4.1+2,2 mg/ml) were significantly lower than those of normal control (24.4+19.1 mg/ml), CPH (25.4+18.5mg/ml), and CAH group (16.6+13.7 mg/ml). The Lp (a) concentrations were significantly correlated with serum albumin concentrations (r=0.54 p<0.05) and prothrombin time (r=0.62, p<0.01). There was a significant difference in mean Lp (a) coincentration between the cases with serum albumin above and below 3.0 g/ml in patients with liver cirrhosis. These data suggest that lipoprotein (a) may be secreted frorn the liver in accordance with the capability of liver to synthesize the protein and we find out that as the liver diseases progressed and deteriorated, the levels of Lp (a) concentrations were significantly decreased.
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
